Ofatumumab, Arzerra*, approved in the USA for the treatment of chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.

Ofatumumab obtained (October 2009) the approval for marketing in the USA under the name of Arzerra*, with he indication chronic lymphocytic leukemia resistant to fludarabine and alemtuzumab. Ofatumumab is a monoclonal antibody directed against CD20 molecule, present at the surface of B-cells.

Ofatumumab requires precautions for its use, it can give many serious adverse effects and does not seem to increase the duration of survival of the patients who receive it.

More information in this FDA document.